An observational study in Dengue, Chikungunya and Zika Virus Infection, sponsored by Institut Pasteur du Cambodge. Recruiting at 1 site in Cambodia. Open to participants aged 2 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by Institut Pasteur du Cambodge · Observational
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.
RACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.
Mathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.
RACSMEI is a nationwide, One Health, multi-pathogen initiative designed to generate integrated evidence for public-health decision-making in Cambodia. Beyond producing epidemiological findings, the project will establish a structured biobank and curated datasets intended to support long-term collaborative research, knowledge sharing, and evidence-informed policy. The program includes capacity building and technology transfer to strengthen national institutions and foster regional scientific leadership and international collaboration. Engagement with communities and national stakeholders is planned to facilitate future studies and promote the uptake of results in practice. Overall, RACSMEI aims to provide a scalable model for integrated infectious-disease assessment in low- and middle-income settings, creating durable infrastructure, partnerships, and decision-support resources that can be used beyond the project period.
283 studies on the registry are indexed under Dengue; 44 are open to participants now.
This study's planned enrollment of 10,000 is above the median of 595 across 80 observational studies indexed under Dengue.
Browse Dengue studies →Institut Pasteur du Cambodge is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population comprises approximately 10,000 participants aged 2 to 75 years, drawn from 4,160 households across Cambodia's 25 provinces. Households will be randomly selected from 104 villages to ensure a nationally representative sample that reflects the country's diverse geographic and demographic characteristics. Participants will provide detailed socio-demographic information, enabling post-stratification weighted analysis of the sample's structure by sex, age, and geographic area to facilitate the extrapolation of findings to the entire population, ensuring that the study's conclusions are broadly applicable.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Probability-based, multi-stage population sample of \~10,000 participants (2-75 years old) recruited across urban and rural communities nationwide. Data include standardized questionnaires (demography, health conditions, mobility, animal contact, healthcare access) and serum biospecimens for multiplex serology;
Seroprevalence of antibodies against an established panel of priority pathogens in the surveyed human populations:
The proportion of sampled individuals with detectable antibodies against this priority panel of pathogens, measured using multiplex serological assays.
Time frame: At the time of blood sampling during household visits, over the inclusion period from December 2025 to April 2026.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Pasteur du Cambodge